Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4855770 | 0.89 | KMT2A (0.48) | AKR1C3ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL27671027 | 0.85 | HTR1A (0.42) | ALDH1A1TSHR | |
| SCHEMBL4853943 | 0.82 | MAPT (0.44) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL4251027 | 0.80 | GPR119 (0.46) | KDM4E | |
| SCHEMBL4254249 | 0.79 | HTR1A (0.41) | CACNA1GCACNA1H | |
| Hydrochloric Acid SCHEMBL4857990 | 0.78 | HTR1A (0.41) | CACNA1GCACNA1H | |
| Hydrochloric Acid SCHEMBL4855946 | 0.77 | HTR1A (0.43) | ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL4857386 | 0.75 | HTR1A (0.49) | CYP2C19HSD17B10TSHR | |
| Hydrochloric Acid SCHEMBL4859541 | 0.75 | HTR1A (0.50) | KDM4E | |
| SCHEMBL27752291 | 0.75 | HTR1A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698620-B1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | EISAI R&D MAN CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-7425554-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7410971-B2 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-08-12 | — | — | US | disclosed |
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112002-A1 | 1,2-di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH1 | AKR1C3 264/4885CYP2C9 1325/4885CYP2C19 2008/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | AKR1C3 303/4885CYP2C9 998/4885CYP2C19 1387/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | AKR1C3 150/4885CYP2C9 1481/4885CYP2C19 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.